SCHEMBL3634237

SCHEMBL3634237

Cc1ccc(S(=O)(=O)N/N=C/C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.56
KMT2A Q03164 9/20 0.55
MEN1 O00255 7/20 0.55
KDM4E B2RXH2 1/20 0.55
F2 P00734 1/20 0.54
PRSS1 P07477 1/20 0.54
PRSS2 P07478 1/20 0.54
PRSS3 P35030 1/20 0.54
POLB P06746 4/20 0.52
RECQL P46063 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MAPT P10636 2/20 0.50
GAA P10253 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3634239 1.00 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1KDM4EF2
SCHEMBL4883526 0.85 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1KDM4EF2
SCHEMBL12749341 0.85 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1KDM4EF2
SCHEMBL11420090 0.84 BCAT1 (0.57) ALDH1A1KMT2AMEN1KDM4EPOLB
SCHEMBL20574290 0.84 BCAT1 (0.57) ALDH1A1KMT2AMEN1KDM4EPOLB
SCHEMBL11406585 0.83 ALDH1A1 (0.55) ALDH1A1KMT2AMEN1KDM4EF2
SCHEMBL28615508 0.83 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1KDM4EF2
SCHEMBL11406582 0.83 MEN1 (0.58) ALDH1A1KMT2AMEN1KDM4EF2
SCHEMBL11408560 0.81 F2 (0.61) ALDH1A1KMT2AMEN1F2PRSS1
SCHEMBL23172046 0.81 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1KDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
EP-4656638-A2 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Japan Tobacco Inc. (JP) 2025-12-03 EP disclosed
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2025-02-13 US disclosed
WO-2025006568-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2025-01-02 WO disclosed
US-20230348438-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-02 US disclosed
US-20230348438-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2023-11-02 US disclosed
US-10934531-B2 Method for enantioselective carbene C—H insertion using an iron-containing protein catalyst CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2021-03-02 US disclosed
US-20200317644-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-08 US disclosed
US-20200317644-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-08 US disclosed
US-20190276805-A1 METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2019-09-12 US disclosed
US-8846746-B2 Pyrazole compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2014-09-30 US disclosed
US-20140073661-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2014-03-13 US disclosed
US-8586600-B2 Heterocyclic compounds and uses thereof CELGENE AVILOMICS RESEARCH, INC. (US) 2013-11-19 US disclosed
US-20130085132-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2013-04-04 US disclosed
US-20130085132-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2013-04-04 US disclosed
US-20120238593-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2012-09-20 US disclosed
US-8242271-B2 Heterocyclic compounds and uses thereof AVILA THERAPEUTICS, INC. (US) 2012-08-14 US disclosed
EP-2152079-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF Avila Therapeutics, Inc. (US) 2010-02-17 EP disclosed
WO-2008151183-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2008-12-11 WO disclosed
US-20080300268-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348438-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF CYP2C19, CYP3A7, CYP3A5 ALDH1A1 1200/4885KMT2A 4152/4885MEN1 1918/4885
US-20080300268-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 ALDH1A1 261/4885KMT2A 3534/4885MEN1 243/4885
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME DUSP2, MKNK2, DUSP22 ALDH1A1 4336/4885KMT2A 506/4885MEN1 1999/4885
US-20130085132-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF SLC5A1, SLC5A2, SLC34A1 ALDH1A1 676/4885KMT2A 2766/4885MEN1 3537/4885
US-20200317644-A1 PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF CYP2C19, CYP3A7, CYP3A5 ALDH1A1 1200/4885KMT2A 4152/4885MEN1 1918/4885
US-20140073661-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 ALDH1A1 261/4885KMT2A 3534/4885MEN1 243/4885
US-20120238593-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF ABCG2, CYP3A5, CYP3A43 ALDH1A1 261/4885KMT2A 3534/4885MEN1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.